Pay-it-forward influenza vaccination among older adults and children: A cost-effectiveness analysis in China.
Journal
PLOS global public health
ISSN: 2767-3375
Titre abrégé: PLOS Glob Public Health
Pays: United States
ID NLM: 9918283779606676
Informations de publication
Date de publication:
2023
2023
Historique:
received:
03
01
2023
accepted:
11
07
2023
medline:
31
8
2023
pubmed:
31
8
2023
entrez:
31
8
2023
Statut:
epublish
Résumé
A quasi-experimental study was conducted to evaluate the effectiveness of a pay-it-forward strategy for increasing influenza vaccination among children and older adults compared to a self-paid vaccination strategy in China. Pay-it-forward is an innovative community-engaged intervention in which participants receive a free influenza vaccination and are then asked if they would like to donate or create a message to support subsequent vaccinations. This economic evaluation used a decision-tree model to compare pay-it-forward to a standard of care arm in which patients had to pay for their own influenza vaccine. The analysis was performed from the healthcare provider perspective and costs were calculated with 2020 United States dollars. The time horizon was one year. In the base case analysis, pay-it-forward was more effective (111 vs 55 people vaccinated) but more costly than standard-of-care ($4477 vs $2725). Pay-it-forward spurred 96.4% (107/111) of individuals to voluntarily donate to support influenza vaccination for high-risk groups in China. Further costing and implementation research is needed to inform scale up.
Identifiants
pubmed: 37651349
doi: 10.1371/journal.pgph.0001590
pii: PGPH-D-23-00017
pmc: PMC10470923
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e0001590Subventions
Organisme : NIAID NIH HHS
ID : R01 AI158826
Pays : United States
Informations de copyright
Copyright: © 2023 Tang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Infect Dis. 2018 Feb 14;217(5):731-741
pubmed: 29220496
Psychol Sex Orientat Gend Divers. 2018 Mar;5(1):1-12
pubmed: 29546228
Nat Med. 2021 Jul;27(7):1142-1144
pubmed: 34127853
Emerg Infect Dis. 2006 Jan;12(1):114-21
pubmed: 16494727
Sci Rep. 2021 Feb 3;11(1):2886
pubmed: 33536462
Vaccine. 2022 Feb 16;40(8):1074-1081
pubmed: 35090777
Bull World Health Organ. 2012 Apr 1;90(4):279-288B
pubmed: 22511824
Lancet Infect Dis. 2020 Aug;20(8):976-982
pubmed: 32530426
Vaccine. 2018 Nov 19;36(48):7262-7269
pubmed: 30340886
Vaccine. 2016 Dec 20;34(52):6707-6714
pubmed: 27773475
Vaccine. 2016 Nov 11;34(47):5724-5735
pubmed: 27745951
Cochrane Database Syst Rev. 2018 May 30;5:CD005188
pubmed: 29845606
BMC Health Serv Res. 2019 Oct 22;19(1):741
pubmed: 31640687
Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5334-8
pubmed: 20212120
Vaccine. 2012 Dec 17;31(1):96-108
pubmed: 23142307
Lancet Infect Dis. 2022 Oct;22(10):1484-1492
pubmed: 35868342
Front Cell Infect Microbiol. 2019 Oct 10;9:344
pubmed: 31649895
J Exp Psychol Gen. 2014 Feb;143(1):247-54
pubmed: 23244034
Sex Transm Dis. 2020 Jun;47(6):395-401
pubmed: 32149952
Influenza Other Respir Viruses. 2009 Jul;3(4):143-9
pubmed: 19627371
Lancet Public Health. 2019 Sep;4(9):e436-e437
pubmed: 31493834
BMJ. 2010 May 17;340:c2220
pubmed: 20478960